Cover Image
市場調查報告書

色覺異常:開發中產品分析

Achromatopsia - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 360907
出版日期 內容資訊 英文 40 Pages
訂單完成後即時交付
價格
Back to Top
色覺異常:開發中產品分析 Achromatopsia - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 40 Pages
簡介

本報告提供色覺異常治療藥的開發情形相關調查分析,提供您開發中產品概要,參與治療藥開發的主要企業及藥物簡介,最新的開發平台趨勢等資訊。

簡介

  • 調查範圍

色覺異常概要

治療藥的開發

  • 開發中產品的概要

色覺異常:企業開發中的治療藥

色覺異常:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

色覺異常:企業開發中的產品

色覺異常治療藥的開發企業

  • Amgen Inc.
  • Applied Genetic Technologies Corporation

色覺異常:治療藥的評估

  • 單劑產品
  • 各給藥途徑
  • 各分子類型

藥物簡介

色覺異常:最近的開發平台趨勢

色覺異常:產品開發的里程碑

  • 主要消息和新聞稿

附錄

目錄
Product Code: GMDHC8087IDB

Summary

Global Markets Direct's, 'Achromatopsia - Pipeline Review, H1 2016', provides an overview of the Achromatopsia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Achromatopsia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Achromatopsia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Achromatopsia
  • The report reviews pipeline therapeutics for Achromatopsia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Achromatopsia therapeutics and enlists all their major and minor projects
  • The report assesses Achromatopsia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Achromatopsia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Achromatopsia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Achromatopsia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Achromatopsia Overview
  • Therapeutics Development
    • Pipeline Products for Achromatopsia - Overview
  • Achromatopsia - Therapeutics under Development by Companies
  • Achromatopsia - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Achromatopsia - Products under Development by Companies
  • Achromatopsia - Companies Involved in Therapeutics Development
    • Amgen Inc.
    • Applied Genetic Technologies Corporation
  • Achromatopsia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Gene Therapy for Achromatopsia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for X-linked retinoschisis and Achromatopsia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate CNGA3 for Achromatopsia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate CNGB3 for Achromatopsia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy to Activate Cone Photoreceptor cGMP-Gated Channel for Achromatopsia - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NT-501 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Achromatopsia - Recent Pipeline Updates
  • Achromatopsia - Product Development Milestones
    • Featured News & Press Releases
      • Apr 20, 2016: AGTC Announces Publication of Safety and Biodistribution Data Supporting Future Clinical Studies of Novel Gene Therapy for Treating Achromatopsia
      • Jan 07, 2016: AGTC Announces Preclinical Data Evaluating Cone-Specific Promoters for Use in Gene Therapy of Achromatopsia and Other Retinal Diseases
      • Nov 23, 2015: AGTC Announces U.S. FDA Orphan Drug Designation for Gene Therapy to Treat Achromatopsia
      • Nov 02, 2015: AGTC Files Investigational New Drug Application for the Treatment of Achromatopsia Caused by Mutations in the CNGB3 Gene
      • Oct 22, 2015: AGTC Announces Orphan Drug Designation in the European Union for Gene Therapy to Treat Achromatopsia
      • Aug 27, 2015: AGTC Announces Achievement of XLRS Patient Enrollment Milestone in Biogen Collaboration
      • May 18, 2015: AGTC Announces New Data Supporting Novel Gene-Based Therapies for Rare Inherited Retinal Diseases
      • May 04, 2015: Novel Gene-Based Therapy for Achromatopsia Demonstrates Functional Rescue of Cone Cells
      • Jul 23, 2013: The University of Florida and AGTC Secure $8.4M Grant to Study Rare Eye Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Achromatopsia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Achromatopsia - Pipeline by Amgen Inc., H1 2016
  • Achromatopsia - Pipeline by Applied Genetic Technologies Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Achromatopsia Therapeutics - Recent Pipeline Updates, H1 2016

List of Figures

  • Number of Products under Development for Achromatopsia, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top